VanEck Biotech ETF (NASDAQ:BBH) Hits New 12-Month High – Still a Buy?

Shares of VanEck Biotech ETF (NASDAQ:BBH) hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $269.90 and last traded at $260.3710, with a volume of 1,235 shares traded. The stock had previously closed at $261.63.

VanEck Biotech ETF Stock Performance

The company has a 50 day simple moving average of $241.94 and a two-hundred day simple moving average of $207.76.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new position in VanEck Biotech ETF during the third quarter worth approximately $788,000. Commonwealth Equity Services LLC acquired a new position in VanEck Biotech ETF in the third quarter valued at $1,009,000. Caldwell Trust Co purchased a new position in VanEck Biotech ETF during the third quarter worth about $47,000. Howard Wealth Management LLC purchased a new position in VanEck Biotech ETF during the third quarter worth about $246,000. Finally, Flagship Harbor Advisors LLC purchased a new position in VanEck Biotech ETF during the third quarter worth about $557,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.